Pharma Product Launch: Why Most Go-To-Market Plans Fail Before Launch Day

A pharma product launch fails when the go-to-market plan is built around the molecule, not the market. The science gets approved, the commercial team gets briefed, and somewhere between regulatory clearance and first prescription, the marketing strategy gets treated as an afterthought. That pattern repeats across the industry with remarkable consistency.

The companies that launch well do something different. They treat the commercial strategy as a parallel workstream to clinical development, not a downstream task. They build HCP engagement, payer access, and patient awareness into the same timeline as the regulatory submission. And they measure launch performance against business outcomes, not campaign activity.

I have spent time on both sides of complex product launches, from managing large media budgets across industries to sitting in rooms where the brief arrives with a regulatory timeline attached and a commercial strategy that amounts to little more than a sales force deployment plan. The structural problem in pharma marketing is not a lack of talent. It is a sequencing problem, and it is almost entirely avoidable.

Why Pharma Launches Underperform in the First 12 Months

The first year after approval is where most of the value in a pharma product launch is either captured or lost. Prescription habits form early. Formulary positioning gets locked. The clinical community forms opinions about where a new therapy fits, and those opinions are sticky. If you are not shaping that conversation before launch, you are reacting to it after.

The core issue is that pharma commercial teams are often structured to execute, not to strategise. The medical affairs team handles pre-approval engagement. The marketing team handles post-approval promotion. The market access team handles payer negotiations. These workstreams frequently run in parallel with minimal integration, which means the go-to-market plan is assembled from separate components rather than designed as a coherent system.

I saw a version of this in a different sector early in my career. When I was at a digital agency and we were pitching for a major brand, the brief had been written by the marketing team without input from the sales team or the commercial director. The campaign we were asked to build was designed to win awards, not customers. The objectives were soft, the measurement framework was vague, and the connection between marketing activity and revenue was assumed rather than engineered. That kind of structural disconnect is not unique to pharma, but in pharma the consequences are more expensive and harder to reverse.

For broader context on how commercial strategy frameworks apply across regulated and complex markets, the articles in the Go-To-Market and Growth Strategy hub cover the structural thinking behind building launch plans that connect marketing activity to business outcomes.

What a Pre-Launch Commercial Strategy Actually Looks Like

Eighteen months before approval is not too early to start building the commercial infrastructure for a pharma product launch. In fact, if you are starting at twelve months, you are already behind on market access, behind on medical education, and behind on the HCP relationships that will determine your early prescription velocity.

The pre-launch phase has four distinct jobs. First, you need to establish the clinical narrative. What is the unmet need this therapy addresses? Where does it sit in the treatment pathway? What does the prescriber need to believe to consider this product as a first or second-line option? These are not marketing questions. They are commercial strategy questions that marketing then executes against.

Second, you need to build your payer strategy before your sales strategy. Formulary access determines whether a prescription can be filled at an acceptable cost to the patient. If you launch with a strong sales force and weak formulary positioning, you will generate prescriptions that convert to abandonments at the pharmacy. That is a waste of sales investment and a damaging first experience for patients and prescribers alike.

Third, you need to audit your digital presence and commercial infrastructure. Before a single promotional asset goes live, your website, your HCP portal, your patient support program, and your CRM need to be functioning as an integrated system. A structured approach to analyzing your web presence for sales and marketing alignment is worth doing at least six months before launch, not six weeks after.

Fourth, you need a medical education strategy that predates your promotional strategy. Peer-reviewed publications, congress presentations, and medical society engagement build the clinical credibility that makes promotional claims credible. You cannot shortcut this. Prescribers are sophisticated. They will triangulate what your sales representatives tell them against what they have read and heard from colleagues. If the clinical evidence base is thin at launch, no amount of promotional spend will compensate.

HCP Engagement: The Channel Strategy That Actually Drives Early Scripts

Healthcare professional engagement has changed significantly over the past decade. The traditional model, where a sales representative visits a physician’s office and delivers a product detail, still exists and still works in certain contexts. But the access constraints on in-person detailing, combined with the shift in how physicians consume clinical information, mean that a pharma product launch that relies primarily on field force coverage is leaving reach on the table.

Digital channels have become central to HCP engagement, and the most effective approach is to meet physicians in the environments where they are already consuming clinical content. This is where endemic advertising becomes strategically important. Reaching HCPs within condition-specific platforms, clinical journals, and professional networks means your message arrives in a context where the audience is already in a clinical mindset. The conversion rates from endemic placements in pharma consistently outperform broad digital buys because the context is doing part of the persuasion work for you.

I have managed media budgets across thirty industries, and the principle holds everywhere: context shapes receptivity. A physician reading about treatment advances in a specialty journal is in a fundamentally different mental state than the same physician scrolling a general news feed. The channel is not just a delivery mechanism. It is part of the message.

Beyond endemic placements, the HCP engagement mix for a launch should include medical education programs, advisory boards, speaker bureau development, and digital detailing tools that allow your field force to deliver richer, more interactive content than a printed leave-behind. The goal is not frequency for its own sake. It is to ensure that the right prescribers have enough clinical confidence in your product to trial it with appropriate patients before the competition establishes its narrative.

There is useful thinking on how intelligent growth models apply to complex commercial environments, and the underlying logic, that growth comes from building the right capabilities in the right sequence, maps directly onto pharma launch planning.

Patient Marketing in Pharma: What the Compliance Framework Misses

Direct-to-consumer pharma advertising, where it is permitted, is one of the most compliance-heavy environments in marketing. Every claim needs to be substantiated. Every piece of promotional material goes through medical, legal, and regulatory review. The result is often marketing that is technically compliant and commercially inert.

The companies that do patient marketing well have figured out how to create genuinely useful content within the compliance framework rather than treating compliance as the ceiling of ambition. Patient support programs, disease awareness campaigns, adherence tools, and condition-specific digital communities can all be built in ways that are compliant and commercially effective. The constraint is not the regulatory framework. It is the imagination of the team working within it.

Patient experience mapping is the analytical foundation here. Understanding where patients are in the diagnosis and treatment pathway, what barriers they face, what information they are searching for, and what emotional states they are handling at each stage gives you a blueprint for content and channel strategy that is genuinely patient-centric rather than just claiming to be.

This is also where the digital infrastructure question becomes critical again. A patient who sees a disease awareness campaign and searches for more information needs to arrive at a resource that is useful, credible, and connected to a support pathway. If the digital experience breaks down at that point, the awareness spend has generated a frustrating dead end rather than a productive next step. The kind of rigorous infrastructure audit that applies to digital marketing due diligence is directly relevant here, because the patient-facing digital estate needs to function as a coherent system, not a collection of separately managed assets.

Market Access and the Commercial Strategy Gap

Market access is the most commercially consequential part of a pharma product launch and the one most frequently treated as a separate function from marketing. That separation is a structural mistake. The value story you build with payers needs to be coherent with the clinical narrative you build with HCPs and the awareness messaging you build with patients. When these three narratives are developed in isolation, you get contradictions that sophisticated stakeholders notice immediately.

The payer value proposition for a new therapy needs to go beyond clinical efficacy. Payers are making resource allocation decisions. They want to understand the budget impact, the comparative effectiveness against existing options, and the real-world outcomes data that supports the clinical trial results. If your market access team is working from a different value framework than your medical affairs team, you will have inconsistent conversations with the people who control formulary access.

Thinking about how value frameworks are built in other complex B2B environments is genuinely useful here. The approach to B2B financial services marketing, where you are selling complex, regulated products to sophisticated institutional buyers, shares more structural DNA with pharma market access than most pharma marketers would recognise. The core discipline is the same: build a value case that speaks to the buyer’s specific decision criteria, not the seller’s product features.

BCG has written on how go-to-market strategy in financial services requires understanding the evolving needs of the buyer population, and the same principle applies to pharma market access. Payer priorities shift. Formulary committee composition changes. The evidence standards that mattered three years ago may have been superseded. Your market access strategy needs to be built on current intelligence, not assumptions carried forward from the last launch.

Building the Launch Measurement Framework Before You Need It

One of the consistent failures I have seen in product launches across industries is the measurement framework being designed after the campaign is live. By that point, the data infrastructure is already set up in ways that make certain questions unanswerable, and the commercial team is making decisions based on whatever metrics happen to be available rather than the ones that actually matter.

In pharma, the lagging indicators, total prescriptions, market share, net revenue, are the ones that get reported to the board. But by the time those numbers are disappointing, the window to course-correct on the underlying drivers has often already closed. Leading indicators are what give you the ability to intervene while there is still time.

The leading indicators worth tracking in a pharma product launch include: formulary wins by payer tier and geography, HCP trial rate among targeted prescribers, patient support program enrollment as a proxy for prescription-to-fill conversion, HCP digital engagement metrics from endemic and owned channels, and sales force call quality metrics rather than just call volume. None of these are perfect proxies for commercial success. But together they give you a picture of whether the commercial engine is functioning before the revenue numbers tell you it is not.

I spent time judging the Effie Awards, which is one of the few places in the industry where marketing effectiveness is evaluated seriously and rigorously. The campaigns that performed best were almost always the ones where the measurement framework was designed at the same time as the creative strategy, not bolted on afterwards. The discipline of asking “how will we know if this worked?” before you spend the money changes the quality of the decisions you make while spending it.

There is also a useful parallel in how pay-per-appointment lead generation structures accountability into the commercial model from the outset. The principle, that you build the measurement of outcomes into the commercial architecture rather than layering it on top, is directly applicable to launch planning.

The Organisational Problem Nobody Talks About

The hardest part of a pharma product launch is not the strategy. It is the organisational alignment required to execute it. You have medical affairs, market access, marketing, sales, regulatory, and often a global headquarters all with legitimate stakes in how the launch is run. The default resolution of competing interests is usually a compromise that satisfies nobody and serves the customer least of all.

The companies that launch well have usually solved the governance problem before they solve the strategy problem. There is a clear commercial lead who has authority over the integrated launch plan. There is a decision-making process that is fast enough to respond to market feedback without requiring committee consensus on every tactical adjustment. And there is a shared definition of success that all functions are accountable to, not separate functional KPIs that can all be green while the launch is red.

When I was running an agency and grew the team from around twenty people to over a hundred, the governance problem was the one that kept appearing in new forms at every stage of growth. At twenty people, alignment is informal. At a hundred, it requires explicit architecture. Pharma launch teams are large, cross-functional, and often geographically distributed. The governance architecture is not a bureaucratic overhead. It is the mechanism that turns individual competence into collective performance.

The corporate and business unit marketing framework for B2B companies addresses exactly this tension between centralised strategy and local execution, and the structural thinking there is directly applicable to how pharma companies organise global versus affiliate launch responsibilities.

Vidyard has written on why go-to-market feels harder than it used to, and the underlying reasons, more stakeholders, more channels, more complexity, more compressed timelines, are all amplified in pharma. The answer is not to add more process. It is to be more deliberate about which decisions require alignment and which ones should be delegated to the people closest to the market.

What Separates a Good Launch Plan from One That Actually Delivers

A good launch plan is coherent. A great launch plan is adaptive. The difference is whether the commercial team has built in the capability to learn from early market signals and adjust before the first quarterly review forces a conversation nobody wants to have.

The agile principles that have transformed software development have genuine application in pharma launch management, not as a methodology to be adopted wholesale, but as a mindset that prioritises learning over planning. BCG has made the case for scaling agile principles in complex organisations, and the core insight, that faster feedback loops produce better outcomes than longer planning cycles, is as true in pharma commercial as it is in product development.

The practical implication is that your launch plan should include explicit decision points where you review leading indicator data and make pre-agreed adjustments to channel mix, message emphasis, or resource allocation. Not a post-mortem after twelve months. A structured review at week six, week twelve, and week twenty-four, with the authority and the data to act on what you find.

Early in my career, I saw how quickly a well-structured campaign could generate commercial results when the brief was clear, the measurement was in place, and the team had the authority to move. A paid search campaign I ran at lastminute.com generated six figures of revenue within roughly a day. The campaign itself was not complicated. What made it work was the clarity of the objective, the quality of the setup, and the fact that nobody was waiting for a committee to approve the next step. Pharma launches are orders of magnitude more complex, but the underlying principle is the same: commercial velocity comes from clarity and decision-making speed, not from the sophistication of the plan.

There are more frameworks for building commercially grounded go-to-market strategies across different sectors and contexts in the Go-To-Market and Growth Strategy hub, and the structural thinking there applies directly to the challenge of building a pharma launch that performs rather than just launches.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions